The traditional HR Business Partner (HRBP) model, once the gold standard for HR delivery, is undergoing a significant transformation. Many organizations, particularly in industries like pharmaceuticals, are moving towards a more agile resource model, aiming to streamline HR operations and…
Lilly Japan Halts Manufacturing of Strattera over Nitrosamine Impurities
To read the full story
Related Article
- Strattera Stock Expected to Run Out as Lilly's Talks with Regulators Drag On
March 24, 2025
- Strattera and All Generic Versions Now under Supply Restrictions in Japan
December 17, 2024
- All Versions of Lilly’s Strattera under Restricted Supplies in Japan
November 26, 2024
- Shipment Curbs Growing for Strattera Generics amid Nitrosamine Issues
November 18, 2024
- Sawai Joins List of Atomoxetine Recalls after Establishing Test Model
September 27, 2024
- 3 More Generic Firms Start Voluntary Recalls of Atomoxetine Products
September 20, 2024
- Don’t Stop Taking Atomoxetine at Own Discretion: MHLW to Patients
September 4, 2024
- MHLW to Set AI Limit for Atomoxetine’s Nitrosamine Impurities at 100 ng/Day
September 2, 2024
BUSINESS
- Leqembi’s FY2024 Sales at 44.3 Billion Yen: Eisai
May 7, 2025
- Lilly’s Eczema Drug Ebglyss Now Available for Self-Injection
May 7, 2025
- Kyowa Kirin’s Q1 Profits Down Over 50% on Higher R&D Spending
May 7, 2025
- Satsuma’s Nasal Powder Drug for Migraine Approved in US
May 7, 2025
- Otsuka's Profit Might Drop by Billions if US Imposes 25% Tariff
May 7, 2025
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…